By Fineline Cube 
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced its financial results for the first half of 2025 on August 6, 2025. The company reported revenue of DKK 154.944 billion (approximately $24.055 billion), marking a year-on-year increase of 18%. Operating profit reached DKK 72.2 billion, reflecting a 29% year-on-year increase.
Revenue Drivers
Global revenue was primarily driven by semaglutide products:
- Ozempic: Sales reached DKK 64.52 billion, up 15% year-on-year.
- Rybelsus: Sales were DKK 11.348 billion, up 5% year-on-year.
- Wegovy: Sales soared to DKK 36.888 billion, up 78% year-on-year.
Therapeutic Area Performance
- Diabetes and Obesity Care: Revenue increased by 18% to DKK 145.4 billion.
- GLP-1 formulation sales: DKK 77.94 billion, up 10% year-on-year.
- Insulin business: DKK 27.743 billion, up 4% year-on-year.
- Obesity product business: DKK 38.796 billion, up 58% year-on-year.
- Rare Disease: Revenue was DKK 9.538 billion, up 15% year-on-year.
Market Performance
- U.S. Market: Revenue of DKK 87.279 billion, up 17% year-on-year.
- Europe and Canada: Revenue of DKK 31.212 billion, up 19% year-on-year.
- Emerging Markets: Revenue of DKK 16.334 billion, up 13% year-on-year.
- Asia-Pacific: Revenue of DKK 10.209 billion, up 12% year-on-year.
- China Market: Revenue of DKK 9.91 billion, up 2% year-on-year.-Fineline Info & Tech